There is recent in vitro and in vivo evidence that somatostatin receptor subtype 2 (sst 2 ) antagonists are better tools to target neuroendocrine tumors (NETs) than sst 2 agonists. Indeed, antagonists bind to a greater number of sst 2 sites than agonists. Whether sst 2 antagonists could be used successfully to target non-NETs, expressing low sst 2 density, is unknown. Here, we compare quantitatively 125 I-JR11 sst 2 antagonist binding in vitro with that of the sst 2 agonist 125 I-Tyr 3 -octreotide in large varieties of non-NET and NET. Methods: In vitro receptor autoradiography was performed with 125 I-JR11 and 125 I-Tyr 3 -octreotide in cancers from prostate, breast, colon, kidney, thyroid, and lymphoid tissues as well as NETs as reference. Results: In general, 125 I-JR11 binds to many more sst 2 sites than 125 I-Tyr 3 -octreotide. In 13 breast cancers, 8 had a low binding (mean density, 844 6 168 dpm/mg of tissue) with the agonist whereas 12 had a high binding (mean density, 4,447 6 1,128 dpm/mg of tissue) with the antagonist. All 12 renal cell cancers showed a low binding of sst 2 with the agonist (mean density, 348 6 49 dpm/mg of tissue) whereas all cases had a high sst 2 binding with the antagonist (mean density, 3,777 6 582 dpm/mg of tissue). One of 5 medullary thyroid cancers was positive with the agonist, whereas 5 of 5 were positive with the antagonist. In 15 nonHodgkin lymphomas, many more sst 2 sites were labeled with the antagonist than with the agonist. In 14 prostate cancers, none had sst 2 binding with the agonist and only 4 had a weak binding with the antagonist. None of 17 colon cancers showed sst 2 sites with the agonist, and only 3 cases were weakly positive with the antagonist. In the various tumor types, adjacent sst 2 -expressing tissues such as vessels, lymphocytes, nerves, mucosa, or stroma were more strongly labeled with the antagonist than with the agonist. The reference NET cases, incubated with a smaller amount of tracer, were also found to have many more sst 2 sites measured with the antagonist. Conclusion: All renal cell cancers and most breast cancers, non-Hodgkin lymphomas, and medullary thyroid cancers represent novel indications for the in vivo radiopeptide targeting of sst 2 by sst 2 antagonists, comparable to NET radiotargeting with sst 2 agonists. Somat ostatin receptors (sst) are highly overexpressed in gastroenteropancreatic and extra-gastrointestinal neuroendocrine tumors (NETs). This represents the molecular basis for sst-targeted diagnostic and therapeutic procedures in NET patients with somatostatin analogs (1-3). One main clinical application makes use of the inhibitory effects of somatostatin on NET cells, particularly on hormone secretion: long-acting somatostatin analogs, such as octreotide or lanreotide, potently inhibit tumoral hormone secretion and improve related symptoms. The second targeting approach is based on the administration of radioactive somatostatin analogs for diagnostic or therapeutic purposes. Indeed, 111 In-octreotide scintigraphy (OctreoScan; Mallinckrodt) and other sst subtype 2 (sst 2 )-targeted imaging with, for example, 68 Ga-DOTATATE, are gold standard methods for NET detection. Moreover, sst radionuclide therapy of NET with 90 Y-or 177 Lu-labeled somatostatin analogs is highly effective and increasingly applied (4,5). Recently, results of the first prospective, randomized, controlled phase III study using radiolabeled somatostatin analogs for peptide receptor radiotherapy were presented. Lutathera ( 177 Lu-DOTATATE) significantly improved progression-free survival in comparison with cold octreotide therapy in advanced midgut NET (6).
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Although it could be shown in vitro that sst 2 antagonists do not trigger receptor internalization (7), we could show in animal models that radiolabeled sst 2 or sst 3 antagonists are not only as good in targeting in vivo the respective receptor, but also even considerably better than the respective agonists (8) . The findings that antagonists for G-protein-coupled receptors (GPCRs) recognize more binding sites than agonists are not new and have been discussed in the literature by several groups (9, 10) . There are only hypotheses in regard to the origin of this difference. The difference is explained by distinct receptor states, those coupling to the G-proteins and uncoupled forms. Antagonists bind to all receptor states whereas agonists bind only to the G-protein-coupled forms that are assumed to represent only a small proportion of the total receptor population (9) . In cancer, GPCRs are frequently overexpressed and the superiority of antagonists was shown for the gastrin-releasing peptide receptor (11), sst2 and sst3 (8) , and the glucose-dependent insulinotropic polypeptide receptor (12) .
A first pilot study in humans using a first-generation sst 2 antagonist confirmed the animal studies (13) . The antagonists were better than agonists for NET imaging (13) . A parallel in vitro study on tissue sections fully confirmed that the 177 Lu-DOTA-bass antagonist labeled more sst 2 binding sites than the 177 Lu-DOTA-TATE agonist (14) . This was observed in NETs but, interestingly, also in a few non-NETs with a low number of sst 2 (14) . Presently, second-generation sst 2 antagonists, such as JR11, are in clinical development, with promising results for diagnosis and targeted radionuclide therapy (15) .
In the present study, we aimed at evaluating the in vitro binding properties of the second-generation antagonist JR11, labeled with 125 I, and compared it with 125 I-Tyr 3 -octreotide, the standard agonist radioligand (16, 17) . 125 I labeling is the optimal choice for in vitro receptor autoradiography quantification (17, 18) . Indeed, 125 I radioligands have been used for decades for receptor autoradiography measurements, and quantification of the data using radioactive reference standards has been routinely performed (18) (19) (20) . The present study therefore allows a direct comparison of quantification data with previously published studies using 125 I radioligands (18) (19) (20) . This is at difference with the previous 177 Lu-DOTA-bass study (14) in which the data using 177 Lu-labeled ligands could not be directly compared with data with 125 I-labeled ligands. In the present study, a large number of tumors, including such tumors with high-density sst 2 (gastroenteropancreatic NET, pheochromocytomas) and those known to express little or no sst 2 (renal cell cancer, breast cancer, prostate cancer, non-Hodgkin lymphoma [NHL], medullary thyroid cancer, colon cancer), were tested with both ligands. Nontumoral tissues, adjacent to the tumors, were also evaluated.
MATERIALS AND METHODS
In a first part, we designed cold iodinated JR-11 (iodo-JR11) (structure: DOTA-Cpa-D-Cys-Aph(L-HOro)-D-Aph(Cbm)-Lys-Thr-Cys D-3-iodo-Tyr-NH2) and measured its binding affinity to sst 2 . Iodo-JR11 was then tested in a displacement experiment using sst 2 -transfected cells in an in vitro autoradiography setting with 125 I-Tyr 3 -octreotide as radioligand, as reported previously (21) . IC 50 (half maximal inhibitory concentration) values were 1.89 6 1.1 nM (n 5 3) for iodo-JR11 and 2.83 6 1.6 nM (n 5 3) for the reference peptide SS-28. The compound iodo-JR11 has therefore high-affinity binding to sst 2 and is suitable as radioligand for the planned cancer experiments.
In a second part, we used 125 I JR-11 (74,000 GBq [2,000 Ci]/mmol; Anawa) as radioligand to evaluate the presence of sst 2 in human breast cancers, renal cell cancers, NHL, medullary thyroid cancers, prostate cancers, colon cancers, pheochromocytomas, paragangliomas, bronchial and ileal NET, and small cell lung cancers. Comparison was done with the agonist tracer 125 I-Tyr 3 -octreotide (74,000 GBq [2,000 Ci]/mmol; Anawa), known to have an IC 50 similar to the antagonist (21). Quantification was performed as previously reported (21) . Specific binding was calculated as total binding minus nonspecific binding for each tumor case. Nonspecific binding was assessed in each case in an adjacent section incubated with 125 I JR-11 or 125 I-Tyr 3 -octreotide in the presence of 100 nM of the unlabeled antagonist or agonist, respectively. The study conformed to the ethical guidelines of the Medical Faculty of the University of Berne. The institutional review board approved this retrospective study and the requirement to obtain informed consent was waived.
RESULTS
One group of tumors, shown previously with sst 2 agonist tracers to have low (,1,000 dpm/mg tissue) levels or a lack of sst 2 , consisting of 13 samples of breast carcinomas, 12 samples of renal cell cancers, 15 samples of NHL, 5 samples of medullary thyroid cancers, 14 samples of prostate cancers, and 17 samples of colon cancers was used in receptor autoradiography experiments as reported previously (22) (23) (24) (25) (26) (27) (28) (29) . Successive sections were incubated in a buffer solution containing the standard amount of 30,000 cpm/100 mL of 125 I-Tyr 3 -octreotide or 30,000 cpm/100 mL of 125 I-JR-11. Quantification was performed as previously reported (21) . Tables 1 and 2 and Supplemental Table 1 (supplemental materials are available at http://jnm.snmjournals.org) show all the results.
A second group of tumors, shown previously with sst 2 agonist tracers to have a high level of sst 2 , consisting of 5 pheochromocytomas, 2 paragangliomas, 4 ileal NET, 1 bronchial NET, and 4 small cell lung cancers, was also used in receptor autoradiography experiments; however, instead of 30,000 cpm/100 mL of tracer, only 10,000 cpm/100 mL of 125 I-Tyr 3 -octreotide or 125 I-JR11 were given. All these cases had been tested previously with 30,000 cpm/100 mL of 125 I-Tyr 3 -octreotide and were shown to express a high density (.2,000 dpm/mg of tissue) of receptors in all cases. The rationale for the strategy to use 10,000 cpm/100 mL of radioligand was that we assumed, based on Cescato et al. (14) , that the antagonist tracer binds to more sites than the agonist and that therefore it is mandatory to use a lesser amount of tracer to prevent overexposure of the films in the antagonist part of the experiment. The results are summarized in Table 3 .
Breast Cancers Table 1 shows that 8 of 13 breast cancer samples express sst using 125 I-Tyr 3 -octreotide, in most of the cases in low density. The mean density of the receptor-positive cases is 844 6 168 dpm/mg of tissue (mean 6 SEM). These data are comparable with previously reported results (22) . With 125 I-JR11, however, sst can be detected in as many as 12 of 13 breast cancers, often in high density. The mean density of the receptor-positive cases is 4,447 6 1,128 dpm/mg of tissue. Figure 1 illustrates the results. Interestingly, although the antagonist labels more sites, the heterogeneity of labeling seen with the agonist is not abolished with the antagonist (Table 1 ), indicating that breast cancers are multiclonal tumors with areas with and without sst. Moreover, the tumoral and peritumoral vessels in the breast cancer samples are sometimes (4/9 cases) weakly labeled with 125 I-Tyr 3 -octreotide. However, with 125 I-JR11, all 9 cases with identified vessels show a moderate to high labeling of these vessels. Therefore, these results are strongly indicative for a markedly higher binding of 125 I-JR11 versus 125 I-Tyr 3 -octreotide.
Renal Cell Cancers Table 1 also shows in a series of 12 renal cell cancers a low level of sst with the agonist in all cases; however, a high density of sst can be identified in all cases with the antagonist. One example is shown in Figure 1 . Mean density value with the agonist is 348 6 49 dpm/mg of tissue (mean 6 SEM) and 3,777 6 582 dpm/mg of tissue with the antagonist, representing a more than 10 times difference. The density values with the antagonist resemble the levels seen in NETs in standard studies with the agonist (18) (19) (20) . As seen previously in breast cancers, a much higher number of binding sites is detected in peritumoral vessels with the antagonist than with the agonist. Table 2 reveals that 4 of 5 medullary thyroid cancers were not labeled with the agonist but that all showed moderate to high labeling with the antagonist. Figure 1 shows a representative example.
Medullary Thyroid Cancers

NHL
Similarly, Table 2 shows that in the 15 NHLs, the antagonist tracer bound to many more sst 2 than the agonist. Whereas the values for the agonist were low or negative, the values measured with the antagonist could be compared with what was seen in NET with the agonist in standard studies (18) (19) (20) . Figure 1 shows a representative example. Here again, tumoral vessels are strongly positive with the antagonist.
Prostate Cancers
Supplemental Table 1 shows that the agonist 125 I-Tyr 3 -octreotide does not detect any sst 2 in the 14 prostate cancer samples, confirming previously published results (23) , whereas the antagonist 125 I-JR11 detects 5 positive cases, 4 of them having only a low sst 2 density. Therefore, the antagonist had a higher sensitivity to detect sst 2 in prostate cancer than the agonist. The higher sensitivity was also observed in the normal adjacent prostate tissues, such as stroma, vessels, or nerves: indeed, whereas these tissues were occasionally labeled with 125 I-Tyr 3 -octreotide, as reported previously as well (23), they were labeled to a much higher level in the experiments with 125 I-JR11. Figure 2 summarizes these results. 
Colon Cancers
Supplemental Table 1 also shows that colon cancers in general do not express significant quantities of sst 2 , either with the agonist or with the antagonist tracer (Fig. 1) , except for 3 cases with borderline levels of receptors as measured with the antagonist radioligand; this density is probably not clinically relevant for tumor targeting. However, in approximately half of the agonist experiments, tumoral vessels, lymphatic follicles, and mucosa are labeled as known from previous studies (30) ; in the antagonist experiments, not only are the vessels, lymphatic follicles, and mucosa labeled in all tested samples, but also the amount of labeling in these compartments is much higher than with the agonist.
NETs
In the series of tumors (Table 3) representing classic indications for sst targeting in vivo, based on the high number of sst, namely pheochromocytomas, paragangliomas, ileal, and bronchial NETs and small cell lung cancers, we have compared agonist and antagonist tracers using a lower amount of tracer of 10,000 cpm/100 mL to prevent overexposure of the films using the antagonist tracer. Despite the lower radioactivity application, the antagonist tracer bound with high levels whereas the agonist tracer bound in general with low levels, as seen in Figure 1 . The difference in binding between antagonist and agonist varied between 2.5-and 40-fold.
DISCUSSION
The comparison of the binding of the sst 2 agonist 125 I-Tyr 3 -octreotide with the sst 2 antagonist 125 I-JR11 showed impressively that the antagonist labeled many more sst 2 binding sites than the agonist, in tumor cells as well as in adjacent sst 2 -expressing tissues. The breast cancer data confirm and expand on the receptor quantification aspect of a previous paper (14) showing that a 177 Lu-labeled sst 2 antagonist labeled more sites than a 177 Lu-labeled sst 2 agonist. On the basis of the high number of 125 I-JR11 binding sites (.2,000 dpm/mg of tissue) in more than half of the tested cases, we conclude in the present study that breast cancers should be added to the list of tumor types that may be successfully targeted in vivo with sst 2 antagonist tracers. A similar conclusion can be drawn for renal cell carcinoma (RCC); the antagonist shows a more than 10 times mean increase in sst 2 binding than with the agonist. Here, 10 of 12 cases showed an sst 2 density higher than 2,000 dpm/mg of tissue. Such values predict a positive sst 2 imaging in vivo in patients (18) . Therefore, RCCs may be considered a serious indication for radiopeptide targeting with sst 2 antagonists. In medullary thyroid cancer and NHL, the antagonist tracer labeled many more sites than the agonist, with 2 of 5 medullary thyroid cancers and 8 of 15 NHLs having an sst 2 density over 2,000 dpm/mg of tissue, respectively. The marked differences between agonist and antagonist binding may be explained by G-protein coupling with the receptor, as discussed above. GPCRs were present in at least 2 affinity states for the radioligands, a small proportion in a GPCR conformation can be labeled by agonists, and a large proportion in a G-proteinindependent (uncoupled) receptor conformation can be labeled by antagonists (9) .
Importantly, in the past, there have been in vivo patient studies using sst 2 agonists that documented the possible feasibility of sst 2 targeting under certain conditions in several nonNETs or tumors expressing only occasionally sst 2 (25) (26) (27) (28) (29) .
Such in vivo studies in patients included targeting of breast cancers (22, 31) , RCCs (32, 33) , NHL (34), prostate cancers (24) , and medullary thyroid cancers (35) . However, as opposed to NETs, there has never been a systematic follow-up and extension of these studies, because it was clear that the predominantly low number of sst 2 detected by the agonist radioligands would prevent a routine application of sst 2 ligands in these indications.
Other types of cancer tested in the present study do not appear to have a significant number of agonist or antagonist binding sites. Indeed, the prostate cancers are unlikely to be an adequate target for JR11, not only because the tumor cells rarely express sst, but also because adjacent tissues, in particular stroma, vessels, and nerves, regularly express sst that may mimic a tumoral sst 2 expression. Similarly, colon cancers seem not to be appropriate tumor types for sst 2 radiotargeting, either with sst 2 agonists or with antagonists.
For comparison, the tumors with an established high density of sst 2 , namely the NETs in Table 3 , show in all cases a massive overexpression of sst 2 with the antagonist, despite the fact that in the present experimental setting the tumor sections were incubated with only one third of the standard radioligand dose. These data confirm what is seen in vivo in patients with gastroenteropancreatic NETs using the sst 2 antagonist JR11, as reported by Wild et al. (15) . Moreover, not only gastrointestinal NETs but also pheochromocytomas, paragangliomas, and lung NETs may be ideally targeted with sst 2 antagonists. In all cases, 125 I-JR11 and 125 I-Tyr 3 -octreotide were given at dose of 10,000 cpm/100 mL incubation solution. 
